Multi-Cancer Early Detection Test Saves Lives

A groundbreaking multi-cancer early detection test (MCED) could reshape cancer screening practices and dramatically improve patient outcomes by identifying malignancies earlier than current standard care. Published in BMJ Open, a recent modeling study shows that annual or biennial use of an MCED test has the potential to detect a wide range of cancers at early stages and reduce late-stage diagnoses and mortality.

How the Multi-Cancer Early Detection Test Works

Unlike traditional cancer screenings that are limited to a few cancers (breast, cervical, colorectal, and lung in high-risk individuals), the MCED test detects chemical signals in the blood indicative of dozens of cancer types. These include cancers of the pancreas, ovary, esophagus, liver, kidney, and blood cancers such as leukemia and lymphoma. The test provides a powerful new approach for identifying asymptomatic cancers, potentially shifting the diagnosis to earlier stages when treatment is more effective.

Modeling the Impact of Regular Multi-Cancer Early Detection Screening

Researchers simulated the outcomes of MCED screenings for individuals aged 50–79 using two scenarios: ‘fast’ tumor growth (stage I lasting 2–4 years) and ‘fast aggressive’ tumor growth (stage I lasting 1–2 years). They evaluated screening intervals ranging from every six months to every three years, with a focus on annual and biennial options.

In the fast-growth scenario, annual MCED screening detected 370 more cancer signals per 100,000 people each year, resulting in 49% fewer late-stage diagnoses and 21% fewer deaths within five years compared to usual care. Biennial screening was slightly less effective, detecting 292 more signals annually and reducing late-stage diagnoses by 39% and deaths by 17%.

Efficiency vs. Effectiveness

While annual screening prevented more deaths in total, biennial screening demonstrated a higher positive predictive value (54% vs. 43%)—indicating more efficient cancer detection per test conducted. Researchers estimate that biennial MCED screening could avert 14% of deaths from aggressive cancers, while annual screening could prevent up to 21%.

What This Means for the Future of Cancer Screening

The findings suggest that integrating an MCED test with existing screening guidelines could intercept a significant number of cancers before they advance. The choice between annual and biennial screening may ultimately depend on practical considerations such as compliance, cost, and health system capacity.

Despite modeling limitations, including assumptions of perfect compliance and test accuracy, the study provides strong evidence for the life-saving potential of multi-cancer early detection tests. As MCED technology evolves and becomes more accessible, it may play a pivotal role in reducing cancer-related mortality on a population scale.

For more information: Yu, Z., et al. (2025). MicroRNA-27a transfected dental pulp stem cells undergo odonto/osteogenic differentiation via targeting DKK3 and SOSTDC1 in Wnt/BMP signaling in vitro and enhance bone formation in vivo. Journal of Translational Medicine. doi.org/10.1186/s12967-025-06208-9.